Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Soleno Therapeutics ( (SLNO) ).
Soleno Therapeutics has addressed a report in the FDA’s Adverse Event Reporting System concerning the death of a 17-year-old patient, which was determined not to be related to their treatment with VYKAT XR. The company emphasizes that VYKAT XR has a proven safety profile and that adverse events will be reported in compliance with legal requirements, while highlighting the complexities of Prader Willi Syndrome, which can lead to various health complications.
The most recent analyst rating on (SLNO) stock is a Buy with a $120.00 price target. To see the full list of analyst forecasts on Soleno Therapeutics stock, see the SLNO Stock Forecast page.
Spark’s Take on SLNO Stock
According to Spark, TipRanks’ AI Analyst, SLNO is a Underperform.
Soleno Therapeutics shows high risk due to its lack of revenue and reliance on external financing. However, it maintains a solid equity base and is experiencing positive technical momentum, suggesting speculative interest. The valuation is typical for an early-stage biotech, with potential upside reliant on successful R&D outcomes.
To see Spark’s full report on SLNO stock, click here.
More about Soleno Therapeutics
Soleno Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on the development and commercialization of treatments for rare diseases, including Prader Willi Syndrome. Its primary product, VYKAT XR, is approved by the FDA and is known for its safety and efficacy.
Average Trading Volume: 1,396,520
Technical Sentiment Signal: Buy
Current Market Cap: $3.84B
For detailed information about SLNO stock, go to TipRanks’ Stock Analysis page.